Figure 3.

Copeptin is a prognostic biomarker for mortality in critically ill patients. A, Patients that died during the course of ICU treatment are characterized by significantly higher plasma copeptin concentrations already at ICU admission. B, Using a calculated cut‐off of 65 pmol/L, high copeptin levels are associated with decreased ICU survival, as depicted by Kaplan‐Meier survival curve analysis. C, Patients that died either at the ICU or during the observation follow‐up period of approximately two years have higher copeptin levels at ICU admission compared to overall survivors. D, Elevated copeptin concentrations (>65 pmol/L) at ICU admission indicate overall mortality during long‐term follow‐up, as depicted by Kaplan‐Meier survival curve analysis